Archive of Postings to PHARM-POLICY
PHARM-POLICY
This is a small "discussion" list which discusses issues relating
to pharmaceutical development. The issues of particular interest
to PHARM-POLICY subscribers are pharmaceutical drug pricing, the
federal government's "reasonable pricing" clause for government
developed drugs, the GATT Intellectual Property provisions as
they relate to compulsory licensing and other similar issues.
Subscription requests to pharm-policy are by electronic mail, sent
to listproc@tap.org, with the message:
subscribe pharm-policy yourfirstname yourlastname
[ Go to the Index of all Archived Lists ]
[ Go to the Index of all Archived Lists ]
[Prev Page][Next Page]
- Parallel Imports in EU - from E-Drug
- From: James Love <love@cptech.org>
- Africa: Women and AIDS
- From: James Love <love@cptech.org>
- Fwd: Fwd: marketing medicines through RCT's
- From: "A Pieters" <A.Pieters.medhistory@med.vu.nl>
- FTC changes Myland with Restrain of Trade, Conspiracy and Monopolization
- From: James Love <love@cptech.org>
- US to support WHA Revised Drug Strategy
- From: James Love <love@cptech.org>
- NCI Role in the Development of 37 Cancer Drugs
- From: James Love <love@cptech.org>
- Mylan price fixing suit
- From: James Love <love@cptech.org>
- Congressinal Report on Prescription Drug Pricing in the US
- From: James Love <love@cptech.org>
- Sneak Prescription Drug Patent Extension in Appropriations Rider
- From: James Love <love@cptech.org>
- Time Magazine on Corporate Welfare and patent extensions
- From: James Love <love@cptech.org>
- Aid for AIDS in Zimbabwe
- From: James Love <love@cptech.org>
- AIDS and compulsory licensing
- From: James Love <love@cptech.org>
- CPT's page on Health Care and the World Health Organization
- From: Catherine Gavin <cgavin@cptech.org>
- public comments on WTO
- From: Catherine Gavin <cgavin@cptech.org>
- Sneak Prescription Drug Patent Extension
- From: James Love <love@cptech.org>
- 1990 Thai Tobacco case --- as precedent for WHA resolution
- From: James Love <love@cptech.org>
- CPT Comments to USTR Regarding FTAA Negotiations -- Health Care comments
- From: James Love <love@cptech.org>
- New Zealand lifts ban on parallel imports -- US Objects
- From: James Love <love@cptech.org>
- Government Funded Drugs
- From: James Love <love@cptech.org>
- Compulsory Licensing Backgrounder
- From: James Love <love@cptech.org>
- Guardian article on Meningitis Patent
- From: James Love <love@cptech.org>
- Health Care and Trade Negotiations Letter to Department of State
- From: James Love <love@cptech.org>
- World Health Assembly Resolution on TRIPS and Public Health
- From: James Love <love@cptech.org>
- WHO resolution - Action taken etc.
- From: consumer unity CUTSCAL trust society <cutscal@cal.vsnl.net.in>
- Meeting Agenda - Workshop on Health Care, IP and Trade Agreements
- From: James Love <love@cptech.org>
- Health Care and USTR IPR "Watch List"
- From: James Love <love@cptech.org>
- USTR's 301 Watch lists On the Web
- From: James Love <love@cptech.org>
- correction on date of WSJ correction
- From: James Love <love@cptech.org>
- Letter to Editor, WSJ
- From: James Love <love@cptech.org>
- Re: WSJ Journal to Issue Retraction
- From: James Love <love@cptech.org>
- WSJ Journal to Issue Retraction
- From: James Love <love@cptech.org>
- Drug makers may get six months extra patent life
- From: James Love <love@cptech.org>
- Correction and addition
- From: James Love <love@cptech.org>
- Amgen comments on EPO invention
- From: James Love <love@cptech.org>
- Wired on Amgen EPO Dispute
- From: James Love <love@cptech.org>
- Reuters story on Amgen EPO
- From: James Love <love@cptech.org>
- Workshop on Intellectual Property,Health Care and International Trade Agreements
- From: James Love <love@cptech.org>
- Letters to Clinton and Binder Re: EPO
- From: James Love <love@cptech.org>
- Investigation of Amgen suppression of EPO invention
- From: James Love <love@cptech.org>
- EPO Background from Amgen 10k
- From: James Love <love@cptech.org>
- NIH and Biotech Sector
- From: James Love <love@cptech.org>
- Essential Facilities Decision in Intel Case
- From: James Love <love@cptech.org>
- New URL for Boston Globe Story
- From: James Love <love@cptech.org>
- Top 10 selling prescription drugs
- From: James Love <love@cptech.org>
- Amgen, EPO and US Pat. 5,625,035
- From: James Love <love@cptech.org>
- Patent-news on Biopatents and the Third World
- From: James Love <love@cptech.org>
- Boston Globe Report on Government funded R&D and pharmaceutical
- From: James Love <love@cptech.org>
- WHA: EBl0l.R24, Revised drug strategy
- From: James Love <love@cptech.org>
- Daley Zuma Meeting Regarding Drug Law
- From: James Love <love@cptech.org>
- FTAA Business Forum closes meetings to public, press and NGOs
- From: James Love <love@cptech.org>
- Medicines & Related Substances Control Amendment Act
- From: James Love <love@cptech.org>
- May 7-8, 1998 Workshop on Intellectual Property, Health Care and International Trade Agreements
- From: James Love <love@cptech.org>
- E-DRUG: HIV trials in developing countries
- From: James Love <love@cptech.org>
- Gene Research
- From: James Love <love@cptech.org>
- US Supreme Court: Parallel Imports of copyrighted goods are OK
- From: James Love <love@cptech.org>
- FDA Letter on Generic Drugs
- From: James Love <love@cptech.org>
- ISREAL: New debate about "Barriers to entry of generic drugs"
- From: James Love <love@cptech.org>
- May 7-8 meeting on Health and IPR
- From: James Love <love@cptech.org>
- University Sponsored medical Research
- From: James Love <love@cptech.org>
- Generic Drug Policy in Mexico under fire from PhRMA
- From: James Love <love@cptech.org>
- PhrMA v Zuma in South Africa
- From: James Love <love@cptech.org>
- Bolar exemption
- From: James Love <love@cptech.org>
- Bolar Roche
- From: James Love <love@cptech.org>
- FTAA sign-on IP position paper
- From: James Love <love@cptech.org>
- Glaxo Wellcom and SmithKline Beechman merger
- From: James Love <love@cptech.org>
- Who owns your genes and body parts
- From: James Love <love@cptech.org>
Mail converted by MHonArc 2.3.3